November 2015
Volume 56, Issue 12
Letters to the Editor  |   November 2015
Use of Clopidogrel and Poor Visual Outcome
Author Affiliations & Notes
  • Jae Hui Kim
    Department of Ophthalmology Kim's Eye Hospital, Konyang University College of Medicine, Seoul, South Korea.
Investigative Ophthalmology & Visual Science November 2015, Vol.56, 7051. doi:10.1167/iovs.15-18111
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jae Hui Kim; Use of Clopidogrel and Poor Visual Outcome. Invest. Ophthalmol. Vis. Sci. 2015;56(12):7051. doi: 10.1167/iovs.15-18111.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements
I read with interest a recent article by Chae et al.,1 which was published in Investigative Ophthalmology & Visual Science. In their study, the use of clopidogrel was associated with poor visual outcome at 2 years. The authors postulated that this association may be related to the association between neovascular age-related macular degeneration (AMD) and cardiovascular disease. 
I agree with the authors' opinion. However, I believe that verifying whether the development of submacular hemorrhage during the follow-up period contributed to the poor visual outcome in patients using clopidogrel may provide useful information to clinicians. It is well known that submacular hemorrhage is associated with poor visual outcome in neovascular AMD. Recently, antivascular endothelial growth factor (VEGF) monotherapy was found to be an effective treatment for this condition.2,3 However, visual acuity was restored to the same level as that before the development of hemorrhage in only a limited proportion of patients,2 suggesting the negative influence of hemorrhage on visual prognosis. Previous studies have shown that the use of anticoagulants, including clopidogrel, is associated with an increased risk of hemorrhage in patients with neovascular AMD.4,5 For this reason, I suspect that the development of submacular hemorrhage during the treatment course may partially influence the poor visual outcome in patients using clopidogrel. A brief description of the incidence of fovea-involving submacular hemorrhage and a comparison of the incidence between patients with and without use of clopidogrel may be helpful to address this question. 
Chae B, Jung JJ, Mrejen S, et al. Baseline predictors for good versus poor visual outcomes in the treatment of neovascular age-related macular degeneration with intravitreal anti-VEGF therapy. Invest Ophthalmol Vis Sci. 2015; 56: 5040–5047.
Kim JH, Chang YS, Kim JW, Kim CG, Yoo SJ, Cho HJ. Intravitreal anti-vascular endothelial growth factor for submacular hemorrhage from choroidal neovascularization. Ophthalmology. 2014; 121: 926–935.
Altaweel MM, Daniel E, Martin DF, et al. Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT). Ophthalmology. 2015; 122: 391–398.
Kiernan DF, Hariprasad SM, Rusu IM, Mehta SV, Mieler WF, Jager RD. Epidemiology of the association between anticoagulants and intraocular hemorrhage in patients with neovascular age-related macular degeneration. Retina. 2010; 30: 1573–1578.
Fine HF, Iranmanesh R, Del Priore LV, et al. Surgical outcomes after massive subretinal hemorrhage secondary to age-related macular degeneration. Retina. 2010; 30: 1588–1594.

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.